Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche

NEXT STORY
This Magic Mushroom Day, Communities Across the Globe Celebrate the Transformative Healing Power of Using Psychedelics as Medicine
PREV STORY
OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial in Secondary Resistant Non-Small Cell Lung Cancer Patients at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
Subscribe to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novan Reports Positive Topline Results with SB208 in Phase 2 Trial

MORRISVILLE, N.C., April 12, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) ...

author_avatar
NASDAQ Market News

Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates

author_avatar
NASDAQ Market News

Achillion’s ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers

author_avatar
NASDAQ Market News